Leerink Partners downgrades Procept Biorobotics to Market Perform
Leerink Partners analyst Mike Kratky downgraded Procept Biorobotics Corp from Outperform to Market Perform and cut the price target to $29 from $31. Procept Biorobotics shares closed at $29.09 on Wednesday.
*this image is generated using AI for illustrative purposes only.
Leerink Partners analyst Mike Kratky has downgraded Procept Biorobotics Corp, reducing the stock's rating from Outperform to Market Perform. The firm also adjusted its valuation expectations, lowering the price target to $29 from the previous $31. Procept Biorobotics shares closed at $29.09 on Wednesday.
The revised rating and price target reflect a shift in the analyst's outlook regarding the company's near-term performance potential relative to the broader market. This adjustment places the stock's target slightly below its current trading level.
Rating and Price Target Changes
The following table outlines the specific changes made by Leerink Partners:
| Metric | Previous Value | New Value |
|---|---|---|
| Rating | Outperform | Market Perform |
| Price Target | $31 | $29 |
What specific factors led Leerink Partners to revise Procept Biorobotics' near-term performance outlook?
How might this downgrade impact investor sentiment and trading volume in the short term?
Are there upcoming clinical trials or product launches that could reverse the revised outlook?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
